Manulife Singapore Partners with Guardant Health to Transform Cancer Care

Date:

Box 1


Box 2

Manulife Singapore has teamed up with Guardant Health to improve access to the cutting-edge Guardant360 liquid biopsy test for eligible customers with advanced solid tumour cancers. This landmark collaboration represents a significant step in advancing cancer care in Singapore, offering patients access to personalised treatment options that may enhance clinical outcomes.

Manulife Singapore Partners with Guardant Health to Transform Cancer Care - Alvinology

The Guardant360 liquid biopsy test provides comprehensive genomic profiling for all advanced solid tumours. It offers critical genomic and epigenomic insights from a simple blood draw, delivering results within just seven days of lab sample receipt. This non-invasive test is especially valuable for patients who lack sufficient tumour tissue for traditional biopsies, helping oncologists quickly identify appropriate treatments.

While specific eligibility criteria and program details will be announced later, this initiative promises to provide Manulife customers with broader access to guideline-recommended biomarkers across all solid cancers.

Box 3





Source link

Box 5

Share post:

spot_img

Popular

More like this
Related

Meta to cut 600 jobs in its AI unit amid ‘organisational bloat’ after hiring spree to scale operations

Facebook owner Meta is reportedly cutting about 600...

SpaceX pulls the plug on Myanmar’s Starlink-fueled scams

SpaceX has disabled more than 2,500 Starlink internet...

Oo La Lab

Hidden in the heart of Delta House lies...